Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 461
- Registration Number
- NCT04540211
- Locations
- 🇭🇰
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong
🇹🇭Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand
🇨🇳Affiliated Hospital of Chengde Medical University, Chengde City, China
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
- Conditions
- Head and Neck CancerOral Mucositis
- Interventions
- Radiation: Intensity-modulated radiation therapy (IMRT)Drug: Cisplatin
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04529850
- Locations
- 🇵🇱
Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland
🇩🇪Universitatsklinikum Leipzig AoR, Leipzig, Germany
🇧🇪Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst, Aalst, Belgium
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 145
- Registration Number
- NCT04526691
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵Showa Univeristy Hospital, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
- Conditions
- Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Interventions
- Drug: SAR408701 (Tusamitamab ravtansine)Drug: PembrolizumabDrug: CisplatinDrug: CarboplatinDrug: Pemetrexed
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT04524689
- Locations
- 🇪🇸
Investigational Site Number : 7240005, La Coruña, A Coruña [La Coruña], Spain
🇪🇸Investigational Site Number : 7240006, Badalona, Catalunya [Cataluña], Spain
🇧🇷Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004, Natal, Rio Grande Do Norte, Brazil
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
- Conditions
- Any Solid TumorGliomaCholangiocarcinomaChondrosarcoma
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT04521686
- Locations
- 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
- Conditions
- Hypopharyngeal Cancer
- Interventions
- Drug: DocetaxelDrug: 5-fluorouracilDrug: CisplatinRadiation: Intensity Modulated Radiation TherapyDrug: Platinum
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 160
- Registration Number
- NCT04502641
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT04495296
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Cervical CarcinomaAdvanced Esophageal CarcinomaAdvanced Gastric CarcinomaAdvanced Head and Neck CarcinomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Lung Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Bile Duct Carcinoma
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT04491942
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
- Conditions
- Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: FluorouracilDrug: CisplatinDrug: IrinotecanDrug: LeucovorinDrug: GemcitabineDrug: OxaliplatinRadiation: Radiation TherapyDrug: Nab-paclitaxel
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT04481204
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Therapy in Biliary Adenocarcinoma
- Conditions
- Biliary CancerCholangiocarcinoma
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Jordan Kharofa
- Registration Number
- NCT04480190
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.